LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Artificial intelligence: investing in new technologies in healthcare

30/09/2021
BLOG

Artificial intelligence: investing in new technologies in healthcare

What if machine learning and artificial intelligence could learn to detect one of the most common forms of blood cancer, through evaluating data based on the gene activity of blood cells(1)?

The biopharmaceutical industry has a long history of handling scientific and patient data and has done so for decades. However, the digitalisation of our society and healthcare systems has resulted in the creation of increasingly vast amounts of data sets, almost impossible for consistent human analysis. AI and machine learning has begun to expand our ability to analyse these increasingly large data sets, thus presenting the opportunity to rapidly develop diagnostics and therapeutics(2).

Encouraging investments in AI

AI is still an evolving technology and this technology continues to improve rapidly. The OECD Recommendation on AI stated that governments should consider “long-term public investment and encourage private investment in R&D, including innovation in trustworthy AI.”

Public investments in the collection of quality data, such as the EU Health Data Space, could allow society to input this data into the AI algorithms, allowing them to learn and grow. However, this data should not be kept in isolation and should be utilised in scientific and medical research allowing more efficient data assessments and applications, reducing the number of required physical trials and burden for patients.

Possible healthcare applications

The possibilities for the use in, and improvement of, modern healthcare are immense. However, in order for people to accept the use of AI in diagnosis and treatment, they will need to be confident in its ability and security. To achieve this, the use of AI should always be ethical, compliant with data privacy laws and there should be strong governance mechanisms.

We supported the Clinical Trials campaign that launched on 30th September within the New Scientist and online.

(1)Stefanie Warnat-Herresthal, Konstantinos Perrakis, Bernd Taschler, Matthias Becker, Kevin Baßler, Marc Beyer, Patrick Günther, Jonas Schulte-Schrepping, Lea Seep, Kathrin Klee, Thomas Ulas, Torsten Haferlach, Sach Mukherjee, Joachim L. Schultze. Scalable prediction of acute myeloid leukemia using high-dimensional machine learning and blood transcriptomics. iScience, 2019; 100780 DOI: 10.1016/j.isci.2019.100780 https://www.sciencedaily.com/releases/2019/12/191223095351.htm
(2)Radakovich, Nathan et al. “Acute myeloid leukemia and artificial intelligence, algorithms and new scores.” Best practice & research. Clinical haematology vol. 33,3 (2020): 101192. doi:10.1016/j.beha.2020.101192

Read it online

Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

Health Biomanufacturing: Feedstock for Preparedness and Resilience


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.